Little mortality is associated with irritable bowel syndrome. However, curative therapy does not exist and the economic impact of this disorder may be considerable.
In this study, investigators from the United States performed a systematic review of the literature.
They included 11 studies which focused on irritable bowel syndrome, and reported direct or indirect costs.
|Total annual productivity costs were $205 million in the United States.|
|Alimentary Pharmacology and Therapeutics|
The team found that the mean direct costs of irritable bowel syndrome management were UK£90, Canadian$259 and US$619 per patient per year.
The total annual direct costs related to irritable bowel syndrome were calculated to be £45.6 million (UK) and $1.35 billion (USA).
Furthermore, the direct resource consumption of all health care for irritable bowel syndrome patients was between US$742 and US$3166.
The team calculated that the total annual productivity costs were $205 million in the United States.
They determined that the total annual expenditure for all health care was significantly higher in irritable bowel syndrome patients than in the controls.
Dr Inadomi's team concluded, "Despite the lack of significant mortality, irritable bowel syndrome is associated with high direct and productivity costs".
"Irritable bowel syndrome patients consume more gastrointestinal-related and more total health care resources than non-irritable bowel syndrome controls, and sustain significantly greater productivity losses".